Keyphrases
Non-carriers
100%
Mismatch Repair Genes
100%
Cancer Screening Program
100%
Pathogenic Variants
100%
Prostate Cancer Screening
100%
Carrier Control
60%
MSH6
53%
MSH2
46%
MLH1
40%
Prostate Cancer
33%
Prostate-specific Antigen
33%
Prostate-specific Antigen Testing
33%
Australia
26%
Positive Predictive Value
20%
Age-matched
13%
Annual Screening
13%
Prostate Cancer Risk
13%
Tumor Characteristics
13%
Cancer Research
13%
Mismatch Repair
13%
Germline Pathogenic Variant
13%
High Incidence
6%
General Hospital
6%
Colorectal Cancer
6%
Early Onset
6%
Disease Pattern
6%
Royal
6%
Cancer Incidence
6%
Cancer Tumor
6%
Germ Cells
6%
Research Support
6%
National Institutes of Health
6%
MSH2 Gene
6%
Urology
6%
Oxford
6%
Histological Analysis
6%
European Ancestry
6%
PMS2
6%
Fisher's Exact Test
6%
Accruals
6%
Male Control
6%
South Australia
6%
Lynch Syndrome
6%
Breast Cancer Susceptibility Gene 1 (BRCA1)
6%
BRCA2
6%
Clinical Research Center
6%
MSH6 Gene
6%
Baker
6%
Cambridge
6%
Prostate-specific Antigen Level
6%
Aggressive Prostate Cancer
6%
Incidence Characteristics
6%
Clinically Significant Cancer
6%
Screening Outcomes
6%
Clinically Significant Prostate Cancer
6%
Malm
6%
Antigen Concentration
6%
Transperineal Prostate Biopsy
6%
Rita Rita
6%
Familial Cancer Syndrome
6%
Tasmania
6%
Catalonia
6%
National Institute for Health Research
6%
Biomedical Research Centres
6%
Salut
6%
National Cancer Institute
6%
Carlos III
6%
Salud
6%
Fundão
6%
Desarrollo
6%
Tecnologia
6%
Endometrial Cancer
6%
NHS Trusts
6%
Total Prostate-specific Antigen
6%
Medicine and Dentistry
Malignant Neoplasm
100%
Prospective Study
100%
Screening
100%
Cancer Screening
100%
Prostate Cancer
100%
Gene Repair
100%
DNA Mismatch Repair
100%
Prostate Specific Antigen
78%
Antigen
35%
Biopsy
21%
Cancer Incidence
21%
Neoplasm
14%
Cancer Research
14%
Disease
7%
Colorectal Cancer
7%
Urology
7%
Disease Predisposition
7%
Clinical Research
7%
Hereditary Nonpolyposis Colorectal Cancer
7%
Biomedical Research
7%
Cancer Syndrome
7%
BRCA2
7%
BRCA1
7%
Fisher Exact Test
7%
Prostate Biopsy
7%
Familial Cancer
7%
Prostate Cancer Diagnosis
7%
Transrectal Ultrasonography
7%
Endometrial Cancer
7%
Biochemistry, Genetics and Molecular Biology
Prospective Study
100%
Screening
100%
Cancer Screening
100%
DNA Mismatch Repair
100%
Gene Repair
100%
Prostate-Specific Antigen
100%
MSH2
81%
MSH6
81%
MLH1
54%
Germ Cell
27%
Cancer Incidence
27%
Germline
27%
Genetics
9%
Sample Size
9%
Clinical Research
9%
PMS2
9%
BRCA1
9%
BRCA2
9%